Simplex Trading, LLC Editas Medicine, Inc. Transaction History

Simplex Trading, LLC

  • $195 Billion
  • Q3 2025

A detailed history of Simplex Trading, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 231,863 shares of EDIT stock, worth $602,843. This represents 0.0% of its overall portfolio holdings.

Number of Shares
231,863
Previous 136,457 69.92%
Holding current value
$602,843
Previous $300,000 168.0%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025
BUY
$2.2 - $3.52 $209,893 - $335,829
95,406 Added 69.92%
231,863 $804,000
Q2 2025

Aug 05, 2025
BUY
$0.98 - $2.35 $2,244 - $5,381
2,290 Added 1.71%
136,457 $300,000
Q1 2025

May 12, 2025
BUY
$1.14 - $3.2 $108,898 - $305,680
95,525 Added 247.21%
134,167 $155,000
Q4 2024

Feb 11, 2025
SELL
$1.2 - $3.76 $15,280 - $47,879
-12,734 Reduced 24.79%
38,642 $49,000
Q3 2024

Nov 08, 2024
SELL
$3.39 - $5.96 $64,125 - $112,739
-18,916 Reduced 26.91%
51,376 $175,000
Q2 2024

Jul 25, 2024
BUY
$4.67 - $7.28 $199,997 - $311,773
42,826 Added 155.92%
70,292 $328,000
Q1 2024

Apr 25, 2024
BUY
$7.03 - $11.07 $193,085 - $304,048
27,466 New
27,466 $203,000
Q3 2023

Nov 01, 2023
BUY
$6.92 - $9.31 $88,928 - $119,642
12,851 Added 101.54%
25,507 $198,000
Q2 2023

Aug 04, 2023
BUY
$6.36 - $11.47 $46,809 - $84,419
7,360 Added 138.97%
12,656 $104,000
Q1 2023

Apr 27, 2023
BUY
$7.03 - $11.53 $37,230 - $61,062
5,296 New
5,296 $38,000
Q3 2022

Nov 04, 2022
BUY
$12.16 - $19.42 $501,818 - $801,424
41,268 New
41,268 $505,000
Q1 2022

May 02, 2022
SELL
$14.08 - $27.63 $405,447 - $795,633
-28,796 Closed
0 $0
Q4 2021

Feb 23, 2022
SELL
$26.55 - $40.57 $1.78 Million - $2.72 Million
-67,080 Reduced 69.97%
28,796 $764,000
Q3 2021

Oct 28, 2021
BUY
$39.27 - $72.94 $16,611 - $30,853
423 Added 0.44%
95,876 $5.42 Million
Q2 2021

Aug 12, 2021
BUY
$31.29 - $56.64 $525,828 - $951,835
16,805 Added 21.37%
95,453 $5.41 Million
Q1 2021

Apr 26, 2021
BUY
$39.71 - $90.58 $3.12 Million - $7.12 Million
78,648 New
78,648 $0
Q4 2020

Feb 02, 2021
SELL
$27.07 - $84.35 $182,181 - $567,675
-6,730 Closed
0 $0
Q3 2020

Oct 14, 2020
SELL
$28.06 - $37.16 $264,465 - $350,232
-9,425 Reduced 58.34%
6,730 $188,000
Q2 2020

Jul 13, 2020
SELL
$18.5 - $34.34 $1.23 Million - $2.28 Million
-66,429 Reduced 80.44%
16,155 $477,000
Q1 2020

Apr 29, 2020
BUY
$14.88 - $32.78 $885,196 - $1.95 Million
59,489 Added 257.58%
82,584 $1.64 Million
Q4 2019

Feb 05, 2020
BUY
$19.49 - $32.63 $372,843 - $624,211
19,130 Added 482.47%
23,095 $683,000
Q3 2019

Oct 15, 2019
BUY
$22.49 - $26.81 $89,172 - $106,301
3,965 New
3,965 $90,000
Q2 2019

Jul 26, 2019
SELL
$20.48 - $27.76 $351,191 - $476,028
-17,148 Closed
0 $0
Q1 2019

Apr 18, 2019
BUY
$19.43 - $26.41 $301,903 - $410,358
15,538 Added 965.09%
17,148 $0
Q4 2018

Jan 16, 2019
SELL
$18.19 - $31.79 $227,320 - $397,279
-12,497 Reduced 88.59%
1,610 $36,000
Q3 2018

Oct 23, 2018
SELL
$27.65 - $38.39 $297,928 - $413,652
-10,775 Reduced 43.3%
14,107 $448,000
Q2 2018

Jul 30, 2018
SELL
$31.4 - $41.01 $193,989 - $253,359
-6,178 Reduced 19.89%
24,882 $891,000
Q1 2018

Apr 26, 2018
BUY
$29.84 - $44.08 $572,182 - $845,234
19,175 Added 161.34%
31,060 $1.03 Million
Q4 2017

Jan 10, 2018
BUY
$21.89 - $31.34 $39,883 - $57,101
1,822 Added 18.11%
11,885 $365,000
Q3 2017

Oct 25, 2017
BUY
$15.81 - $24.01 $159,096 - $241,612
10,063
10,063 $241,000

Others Institutions Holding EDIT

# of Institutions
225
Shares Held
46.2M
Call Options Held
841K
Put Options Held
304K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $179M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email